Umber Cheema

2 months ago | pubs.acs.org | Priyanka Gupta |Umber Cheema |Andrew Nisbet |Anna-Dimitra Kataki

1. IntroductionClick to copy section linkSection link copied!Termed as a “silent killer,” pancreatic ductal adenocarcinoma (PDAC), a malignancy of the pancreas, exhibits a devastating 5-year survival rate of only ∼13% with minimal improvement observed over the past decade. (1) A key factor contributing to these disheartening outcomes is the significant resistance of PDAC to conventional treatment modalities, including chemotherapy and radiotherapy.